Abstract:Idiopathic pulmonary fibrosis (IPF) is a progressive, eventually fatal disease. IPF is characterized by excessive accumulation of the extracellular matrix (ECM) in the alveolar parenchyma and progressive lung scarring. The pathogenesis of IPF and whether the ECM involved in the process remain unknown. To identify potential treatment target and ECM associated proteins that may be involved in the development of IPF, we employed isobaric tag for relative and absolute quantitation (iTRAQ) combined liquid chromatography–tandem mass spectrometry (LC–MS/MS) approach to examine protein expression in lung tissues from IPF patients. A total of 662 proteins with altered expression (455 upregulated proteins and 207 downregulated proteins) were identified in lung tissue of IPF patients compared with control. KEGG pathway enrichment analysis showed that the altered proteins in lung tissue mainly belonged to the PI3K-Akt signaling, focal adhesion, ECM-receptor interaction, and carbon metabolism pathways. According to the bioinformatic definition of the matrisome, 229 matrisome proteins were identified in lung tissue. These proteins comprised the ECM of lung, of which 104 were core matrisome proteins, and 125 were matrisome-associated proteins. Of the 229 ECM quantified proteins, 56 significantly differentially expressed proteins (19 upregulated proteins and 37 downregulated proteins) were detected in IPF lung tissue samples. In addition to proteins with well-known functions such as COL1A1, SCGB1A1, TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSPG2, and SERPINB3, we identified several novel ECM proteins with unknown function deposited in IPF lung tissue including LGALS7, ASPN, HSP90AA1 and HSP90AB1. Some of these differentially expressed proteins were further verified using Western blot analysis and immunohistochemical staining. This study provides a list of proteomes that were detected in IPF lung tissue by iTRAQ technology combined with LC–MS/MS. The findings of this study will contribute better understanding to the pathogenesis of IPF and facilitate the development of therapeutic targets.

Research Progress on Proteomics of Idiopathic Pulmonary Fibrosis

Predictors of Progression in Idiopathic Inflammatory Myopathies with Interstitial Lung Disease

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis

Serum proteomics identify biomarkers associated with the pathogenesis of idiopathic pulmonary fibrosis

Serum Proteomics Identifies Biomarkers Associated with the Pathogenesis of Idiopathic Pulmonary Fibrosis

Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction

Quantitative Proteomic Characterization of Lung Tissue in Idiopathic Pulmonary Fibrosis

Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis

Proteomic profiling of formalin-fixed paraffine-embedded tissue reveals key proteins related to lung dysfunction in idiopathic pulmonary fibrosis

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Biomarkers for Early Diagnosis of Idiopathic Pulmonary Fibrosis: A Systematic Review

Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis

Progress in Treatment of Idiopathic Pulmonary Fibrosis

Proteomic Analysis of the Serum in Patients with Idiopathic Pulmonary Arterial Hypertension

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Predicting biomarkers related to idiopathic pulmonary fibrosis: Robust ranking aggregation analysis and animal experiment verification

Cytokine Network in Pathogenesis of Idiopathic Pulmonary Fibrosis

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies

Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers